A detailed history of Nuveen Asset Management, LLC transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 190,906 shares of DAWN stock, worth $2.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
190,906
Previous 175,775 8.61%
Holding current value
$2.7 Million
Previous $2.9 Million 9.4%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$12.03 - $17.69 $182,025 - $267,667
15,131 Added 8.61%
190,906 $2.63 Million
Q4 2023

Feb 14, 2024

SELL
$9.68 - $15.37 $2.41 Million - $3.83 Million
-249,434 Reduced 58.66%
175,775 $2.57 Million
Q3 2023

Nov 14, 2023

BUY
$11.22 - $14.86 $812,810 - $1.08 Million
72,443 Added 20.54%
425,209 $5.22 Million
Q2 2023

Aug 14, 2023

SELL
$11.74 - $14.47 $1.71 Million - $2.11 Million
-146,025 Reduced 29.28%
352,766 $4.21 Million
Q1 2023

May 15, 2023

BUY
$12.75 - $23.41 $990,216 - $1.82 Million
77,664 Added 18.44%
498,791 $6.67 Million
Q4 2022

Feb 14, 2023

SELL
$18.77 - $22.0 $518,859 - $608,146
-27,643 Reduced 6.16%
421,127 $2.79 Million
Q3 2022

Nov 14, 2022

BUY
$16.44 - $26.57 $6.19 Million - $10 Million
376,218 Added 518.55%
448,770 $2.97 Million
Q2 2022

Aug 15, 2022

BUY
$5.72 - $17.9 $187,490 - $586,726
32,778 Added 82.41%
72,552 $481,000
Q1 2022

May 16, 2022

BUY
$9.12 - $17.47 $226,294 - $433,483
24,813 Added 165.85%
39,774 $391,000
Q3 2021

Nov 12, 2021

BUY
$20.0 - $27.92 $299,220 - $417,711
14,961 New
14,961 $355,000

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $1.04B
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.